| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 50419-0511-06 | 50419-0511 | Fludarabine | Fludara | Chemotherapy | Antimetabolite | Purine Analog | Intravenous | Apr 18, 1991 | Jun 30, 2013 | No Longer Used | |
| 61703-0600-05 | 61703-0600 | Carboplatin | Carboplatin | 10.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | May 23, 2022 | In Use | |
| 70710-1674-01 | 70710-1674 | Pemetrexed disodium | Pemetrexed | 1000.0 mg/40mL | Chemotherapy | Antimetabolite | Folic Acid Analog | Intravenous | May 26, 2022 | In Use | |
| 50242-0084-08 | 50242-0084 | Inavolisib | Itovebi | 3.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K⍺ | Oral | Oct 14, 2024 | In Use | |
| 66758-0054-02 | 66758-0054 | Fluorouracil | Fluorouracil | 50.0 mg/mL | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous | May 2, 2011 | May 2, 2011 | In Use |
| 51991-0377-05 | 51991-0377 | IMATINIB MESYLATE | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | Jun 30, 2023 | No Longer Used |
| 51991-0823-28 | 51991-0823 | Everolimus | Everolimus | 7.5 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | Mar 5, 2021 | In Use | |
| 63850-0061-04 | 63850-0061 | Everolimus | Everolimus | 10.0 mg/1 | Chemotherapy | Enzyme Inhibitor | mTOR | Oral | May 26, 2023 | In Use | |
| 72266-0253-01 | 72266-0253 | Cisplatin | CISPLATIN | 1.0 mg/mL | Chemotherapy | Alkylating Agent | Platinum Compound | Intravenous | Aug 11, 2023 | In Use | |
| 00078-0923-61 | 00078-0923 | letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
| 00078-0909-61 | 00078-0909 | letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
| 00078-0916-61 | 00078-0916 | Letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
| 00185-0933-86 | 00185-0933 | Cyclosporine | Cyclosporine | 100.0 mg/1 | Ancillary Therapy | Immunomodulator | Calcineurin Inhibitor | Oral | Nov 21, 2015 | Feb 28, 2020 | No Longer Used |
| 47335-0715-13 | 47335-0715 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 25, 2022 | No Longer Used | |
| 35356-0197-65 | 35356-0197 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 10, 2010 | Jun 30, 2025 | No Longer Used |
| 54569-5873-01 | 54569-5873 | Ondansetron, ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | May 4, 2016 | In Use | |
| 25021-0826-67 | 25021-0826 | Zoledronic Acid | Zoledronic Acid | 0.04 mg/mL | Ancillary Therapy | Bisphosphonate | Intravenous | Sep 1, 2015 | In Use | ||
| 51662-1246-04 | 51662-1246 | ONDANSETRON | ONDANSETRON | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Nov 19, 2018 | In Use | |
| 60687-0227-11 | 60687-0227 | Leucovorin Calcium | Leucovorin Calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Jan 24, 2017 | In Use | |
| 00781-1681-01 | 00781-1681 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Dec 1, 2015 | No Longer Used |
| 63187-0256-06 | 63187-0256 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 24, 2024 | In Use | |
| 58118-1459-00 | 58118-1459 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jun 25, 2007 | Jun 26, 2017 | No Longer Used |
| 68788-9670-03 | 68788-9670 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jul 24, 2013 | In Use | |
| 63187-0513-15 | 63187-0513 | ondansetron hydrochloride | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 1, 2018 | In Use | |
| 50436-0446-03 | 50436-0446 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Aug 18, 2011 | Dec 31, 2017 | In Use |
Found 12250 results — Export these results
Home